[go: up one dir, main page]

MX2013013281A - Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca. - Google Patents

Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.

Info

Publication number
MX2013013281A
MX2013013281A MX2013013281A MX2013013281A MX2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A MX 2013013281 A MX2013013281 A MX 2013013281A
Authority
MX
Mexico
Prior art keywords
cathepsin
treatment
heart failure
pulmonary hypertension
prophylaxis
Prior art date
Application number
MX2013013281A
Other languages
English (en)
Inventor
Heinrich Meier
Stefan Golz
Martina Delbeck
Hubert Truebel
Andreas Geerts
Thomas Mondritzki
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2013013281A publication Critical patent/MX2013013281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de inhibidbres de la catepsina K y/o catepsina S en un procedimiento para el tratamiento y/o la profilaxis de hipertensión pulmonar y/o insuficiencia cardiaca.
MX2013013281A 2011-05-16 2012-05-11 Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca. MX2013013281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166229 2011-05-16
PCT/EP2012/058773 WO2012156311A1 (en) 2011-05-16 2012-05-11 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Publications (1)

Publication Number Publication Date
MX2013013281A true MX2013013281A (es) 2013-12-06

Family

ID=46085031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013281A MX2013013281A (es) 2011-05-16 2012-05-11 Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.

Country Status (15)

Country Link
US (1) US9943522B2 (es)
EP (1) EP2709602B1 (es)
JP (1) JP6000340B2 (es)
KR (1) KR20140034821A (es)
CN (1) CN103687593B (es)
AU (1) AU2012257779A1 (es)
BR (1) BR112013029672A2 (es)
CA (1) CA2835913A1 (es)
ES (1) ES2648819T3 (es)
IL (1) IL229312A0 (es)
MX (1) MX2013013281A (es)
RU (1) RU2013155509A (es)
SG (1) SG194842A1 (es)
WO (1) WO2012156311A1 (es)
ZA (1) ZA201308391B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029672A2 (pt) 2011-05-16 2017-01-17 Bayer Ip Gmbh uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
CN109864990B (zh) * 2017-12-05 2022-07-15 中国医学科学院药物研究所 巴利卡替在制备抗丝状病毒感染药物中的应用
CN110981937B (zh) * 2018-09-30 2021-11-12 北京和理咨询有限公司 Odn或衍生物的多肽偶合物及其制备方法和应用
US20230142126A1 (en) * 2020-05-15 2023-05-11 Healion Bio., Inc. Methods and compositions for the treatment of viral diseases
WO2022072504A1 (en) * 2020-09-29 2022-04-07 Healion Bio, Inc. Methods and compositions for the treatment of viral diseases
WO2024177898A1 (en) * 2023-02-22 2024-08-29 The Board Of Regents Of The University Of Texas System Cleavage products of angiopoietin-2 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1022276T3 (da) 1997-09-04 2003-09-29 Nippon Chemiphar Co Epoxysuccinamidderivater
BR9916488A (pt) 1998-12-23 2001-10-09 Smithkline Beecham Corp Inibidores de protease
CZ20013248A3 (cs) 1999-03-15 2002-04-17 Axys Pharmaceuticals, Inc. Nové sloučeniny a prostředky jako inhibitory proteázy
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
MXPA02009305A (es) 2000-03-21 2003-03-12 Smithkline Beecham Corp Inhibidores de proteasa.
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20040009171A1 (en) 2001-10-18 2004-01-15 Genentech, Inc. Methods for the treatment of carcinoma
NZ534583A (en) * 2002-03-05 2006-11-30 Axys Pharm Inc Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors
AU2002333956A1 (en) 2002-07-04 2004-02-02 Aventis Pharma S.A. Novel thiophene acyl hydrazino derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
WO2004058238A1 (en) 2002-12-23 2004-07-15 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
US7585988B2 (en) 2003-04-25 2009-09-08 Nippon Chemiphar Co., Ltd. Salt of (2S, 3S) -3- [[(1S) -1- isobutoxymethyl-3-methylbutyl] carbamoly] oxirane-2-carboxylic acid
WO2006076796A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and obesity
WO2006076797A1 (en) 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
CN103172568A (zh) 2005-07-06 2013-06-26 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
CA2721838C (en) * 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US10092580B2 (en) * 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
BR112013029672A2 (pt) 2011-05-16 2017-01-17 Bayer Ip Gmbh uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca

Also Published As

Publication number Publication date
AU2012257779A1 (en) 2013-11-28
KR20140034821A (ko) 2014-03-20
US20140155383A1 (en) 2014-06-05
CN103687593B (zh) 2016-09-28
RU2013155509A (ru) 2015-06-27
WO2012156311A1 (en) 2012-11-22
SG194842A1 (en) 2013-12-30
EP2709602A1 (en) 2014-03-26
JP6000340B2 (ja) 2016-09-28
US9943522B2 (en) 2018-04-17
EP2709602B1 (en) 2017-08-23
BR112013029672A2 (pt) 2017-01-17
ES2648819T3 (es) 2018-01-08
ZA201308391B (en) 2015-02-25
IL229312A0 (en) 2014-01-30
CA2835913A1 (en) 2012-11-22
JP2014518868A (ja) 2014-08-07
CN103687593A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2013013281A (es) Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
PH12015501108A1 (en) Treatment of pulmonary disease
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014CN04634A (es)
WO2012156537A3 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of thrombosis and cardiovascular diseases
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
WO2012142498A3 (en) Mif inhibitors and their uses
PH12013501871A1 (en) Cyclopropylamines as lsd1 inhibitors
EA201500362A1 (ru) Ингибиторы rho-киназы
WO2012156531A9 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MY167126A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
WO2012038504A3 (en) Breast cancer therapeutics
EP2595482A4 (en) INHIBITORS OF ALDOSTERONE SYNTHASE
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2011083482A3 (en) Method for treatment of psoriasis
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
IN2014DN08443A (es)
GB2510524A (en) Pulmonary hypertension

Legal Events

Date Code Title Description
FA Abandonment or withdrawal